Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice

The paper considers modern conceptions about the role of citoprotective therapy in persons with ischemic heart disease. Special attention is given to the justification of Trimetazidine modified release (TMZ MV) application in patients with severe multi-vessel coronary lesions in conjunction with lef...

Full description

Bibliographic Details
Main Authors: A. V Barsukov, D. V Glukhovskoy
Format: Article
Language:English
Published: Concilium Medicum 2014-03-01
Series:КардиоСоматика
Subjects:
Online Access:https://cardiosomatics.orscience.ru/2221-7185/article/view/45087
_version_ 1818721598790696960
author A. V Barsukov
D. V Glukhovskoy
author_facet A. V Barsukov
D. V Glukhovskoy
author_sort A. V Barsukov
collection DOAJ
description The paper considers modern conceptions about the role of citoprotective therapy in persons with ischemic heart disease. Special attention is given to the justification of Trimetazidine modified release (TMZ MV) application in patients with severe multi-vessel coronary lesions in conjunction with left ventricular systolic dysfunction. There described the clinical case with emphasis on possibility of inclusion in conservative treatment scheme of TMZ MB to poly morbid elderly patient with severe ischemic heart disease.
first_indexed 2024-12-17T20:41:17Z
format Article
id doaj.art-4e42dbcc7de54471bcfb775f7b1935b1
institution Directory Open Access Journal
issn 2221-7185
2658-5707
language English
last_indexed 2024-12-17T20:41:17Z
publishDate 2014-03-01
publisher Concilium Medicum
record_format Article
series КардиоСоматика
spelling doaj.art-4e42dbcc7de54471bcfb775f7b1935b12022-12-21T21:33:19ZengConcilium MedicumКардиоСоматика2221-71852658-57072014-03-0151566240752Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practiceA. V Barsukov0D. V Glukhovskoy1Military medical academy named after S.M.Kirov, Saint−PetersburgMilitary medical academy named after S.M.Kirov, Saint−PetersburgThe paper considers modern conceptions about the role of citoprotective therapy in persons with ischemic heart disease. Special attention is given to the justification of Trimetazidine modified release (TMZ MV) application in patients with severe multi-vessel coronary lesions in conjunction with left ventricular systolic dysfunction. There described the clinical case with emphasis on possibility of inclusion in conservative treatment scheme of TMZ MB to poly morbid elderly patient with severe ischemic heart disease.https://cardiosomatics.orscience.ru/2221-7185/article/view/45087ischemic heart diseasemultivessel lesionsystolic dysfunctiondrug treatmenttrimetazidine modified release
spellingShingle A. V Barsukov
D. V Glukhovskoy
Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice
КардиоСоматика
ischemic heart disease
multivessel lesion
systolic dysfunction
drug treatment
trimetazidine modified release
title Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice
title_full Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice
title_fullStr Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice
title_full_unstemmed Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice
title_short Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice
title_sort trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease from the theory to real clinical practice
topic ischemic heart disease
multivessel lesion
systolic dysfunction
drug treatment
trimetazidine modified release
url https://cardiosomatics.orscience.ru/2221-7185/article/view/45087
work_keys_str_mv AT avbarsukov trimetazidinemodifiedreleaseintreatmentofpatientswiththeseriouscourseofchronicischemicheartdiseasefromthetheorytorealclinicalpractice
AT dvglukhovskoy trimetazidinemodifiedreleaseintreatmentofpatientswiththeseriouscourseofchronicischemicheartdiseasefromthetheorytorealclinicalpractice